Healthcare -
Biotechnology - NASDAQ - US
$ 4.055
2.66 %
$ 249 M
Market Cap
-4.14
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Monte Rosa Therapeutics, Inc.
| Net Income | -72.7 M |
| Depreciation & Amortization | 8.12 M |
| Capital Expenditures | -3.99 M |
| Stock-Based Compensation | 18.1 M |
| Change in Working Capital | 91.4 M |
| Others | 81.9 M |
| Free Cash Flow | 38 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (72.7) | (135.4) | (108.5) | (74.0) | (35.9) | (7.7) |
| Depreciation & Amortization | 8.1 | 6.2 | 3.7 | 2.1 | 0.5 | 72 K |
| Deferred Income Tax | 0 | 0 | 0 | 17 K | 0 | 0 |
| Stock Based Compensation | 18.1 | 16.7 | 11.7 | 5.2 | 0.4 | 0 |
| Other Operating Activities | (2.9) | (3.8) | 2.8 | 1.0 | 7.7 | (0.3) |
| Change in Working Capital | 91.4 | 72.5 | (2.1) | 6.3 | 4.3 | 1.8 |
| Cash From Operations | 42.0 | (43.8) | (92.5) | (59.4) | (23.1) | (6.2) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (4.0) | (19.0) | (12.9) | (9.7) | (3.4) | (1.4) |
| Other Items | (40.5) | 107.8 | (206.3) | 79 K | 0 | 0 |
| Cash From Investing Activities | (44.5) | 88.8 | (219.2) | (9.7) | (3.4) | (1.4) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | (0.6) | 0 | 0 | 0 | (0.4) | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0.8 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 98.6 | 27.5 | 0.4 | 139.8 | 60.5 | 14.2 |
| Cash From Financing Activities | 98.9 | 27.5 | 20.5 | 377.6 | 60.1 | 15.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 96.4 | 72.5 | (291.2) | 308.5 | 33.6 | 7.4 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | 38.0 | (62.8) | (105.4) | (69.1) | (26.4) | (7.6) |